Risk treatment thresholds for initiating cardiovascular disease pharmacotherapy: Synthesis of international evidence to support guideline recommendations.

Background: A new Australian guideline for cardiovascular disease (CVD) risk assessment and management was published in 2023, including new risk treatment thresholds.

Objective: This article summarises the published peer-reviewed global evidence that informed guideline recommendations on risk treatment thresholds for initiating blood pressure- and lipid-lowering therapy for CVD primary prevention.

Discussion: Evidence from 13 meta-analyses, randomised controlled trials and modelling studies involving more than 515,700 patients showed that preventive pharmacotherapy reduced the number of CVD events at all risk levels.

Quality of life, depression and correlates in HIV+ people at An Hoa Clinic, Ho Chi Minh City.

This study investigated correlates of quality of life (QOL) among people living with HIV/AIDS (PLWH) at An Hoa Clinic, Ho Chi Minh City, Vietnam. Inclusive criteria were PLWH ≥18 years old, under antiretroviral therapy (ART) for ≥3 months, and consent to participate. PLWH who were illiterate, too ill, or at the final stage of AIDS were excluded.